[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

20:41 EDT 27 Jun 2013 | The Lancet

A recommended phase 2 dose of 300 mg/day niraparib is well tolerated. Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.

Original Article: [Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial"

Search BioPortfolio:
Advertisement

Relevant Topics

Bioinformatics
Latest News Clinical Trials Research Drugs Reports Corporate
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cancer Disease
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Advertisement

Searches Linking to this Story